PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery

Gu, Shanshan, Cui, Danrui, Chen, Xiaoyu, Xiong, Xiufang, Zhao, Yongchao·2018·BioEssays
DOI 10.1002/bies.201700247

Cited by (239)

Items 101–200 of 239

  1. High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
    Kristin M. Riching, Sarah D. Mahan, Marjeta Urh, Danette L. Daniels · 2020 · Journal of Visualized Experiments
  2. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy
    Ying Ma, Brian J. North, Jianfeng Shu · 2021 · Molecular Biology Reports
  3. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase
    Haili Wang, Chuchu Li, Xiaoqing Liu, Ming‐Liang Ma · 2022 · Bioorganic & Medicinal Chemistry
  4. Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications
    Pascal Heitel · 2023 · Molecules
  5. TACkling Cancer by Targeting Selective Protein Degradation
    María del Mar Noblejas‐López, David Tébar-García, Raquel López‐Rosa, Ana Lucía Alcaraz-Sanabria, Pablo Cristóbal‐Cueto, Alejandro Pinedo‐Serrano, Lorenzo Rivas‐García, Eva María Galán‐Moya · 2023 · Pharmaceutics
  6. A self-assembled affibody-PROTAC conjugate nanomedicine for targeted cancer therapy
    Qingrong Li, Xiaoyuan Yang, Mengqiao Zhao, Xuelin Xia, Wenhui Gao, Wei Huang, Xiao‐Xia Xia, Deyue Yan · 2024 · Nano Research
  7. Strategy and Design of In Situ Activated Protein Hydrolysis Targeted Chimeras
    Mei-Yu Lv, Da‐Yong Hou, Shaowei Liu, Dong‐Bing Cheng, Haoran Wang · 2024 · ACS Nano
  8. Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies
    Zheng Zhang, Xiaolan Xing, Peng Fei Guan, Shubin Song, Guirong You, Chengcai Xia, Tingting Liu · 2021 · European Journal of Medicinal Chemistry
  9. Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs
    Mohd. Muddassir, Kunjal V. Soni, Chetan B. Sangani, Abdullah Saad AlArifi, Mohd Faiz Afzal, Naaser A. Y. Abduh, Yongtao Duan, Poonam Bhadja · 2020 · RSC Advances
  10. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
    Elona Cekani, Samantha Epistolio, Giulia Dazio, Marco Cefalì, Luciano Wannesson, Milo Frattini, Patrizia Froesch · 2022 · Cancers
  11. Strategies to Investigate Ubiquitination in Huntington's Disease
    Sap, Karen A., Reits, Eric A. · 2020 · Frontiers in Chemistry
  12. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy–Lysosome Pathway
    Katelyn B. Cassidy, Heng Zhao · 2021 · Biochemistry
  13. ELIOT : A platform to navigate the E3 pocketome and aid the design of new PROTACs
    Tommaso Palomba, Massimo Baroni, Simon Cross, Gabriele Cruciani, Lydia Siragusa · 2022 · Chemical Biology & Drug Design
  14. PROTAC: Novel degradable approach for different targets to treat breast cancer
    Zhenjie Wang, Siyao Che, Zhiqiang Yu · 2024 · European Journal of Pharmaceutical Sciences
  15. ETV6 gene aberrations in non-haematological malignancies: A review highlighting ETV6 associated fusion genes in solid tumors
    Angana Biswas, Yetirajam Rajesh, Pralay Mitra, Mahitosh Mandal · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  16. CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
    Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, S. Renuka Jyothi, Irwanjot Kaur, Sachin Kumar, Naveen Sharma, G. V. Siva Prasad, Atreyi Pramanik, Haider Ali · 2024 · Chemical Biology & Drug Design
  17. Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation
    Shareef Shaik, Prasanna Kumar Reddy Gayam, Manish Chaudhary, Gurvinder Singh, Aravinda Pai · 2024 · Bioorganic Chemistry
  18. Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons
    Saooda Ibrahim, Muhammad Umer Khan, Iqra Khurram, Raima Rehman, Abdur Rauf, Zubair Ahmad, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Mohammed Mansour Quradha · 2025 · Food Science & Nutrition
  19. Harnessing PROTAC technology to combat stress hormone receptor activation
    Mahshid Gazorpak, Karina M. Hugentobler, Dominique Paul, Pierre‐Luc Germain, Miriam Kretschmer, Iryna Ivanova, Selina Frei, Kei H Mathis, Remo Rudolf, Sergio Mompart Barrenechea et al. · 2023 · Nature Communications
  20. Small Molecule Inhibitors Targeting the “Undruggable” Survivin: The Past, Present, and Future from a Medicinal Chemist’s Perspective
    Qingbin Cui, Caoqinglong Huang, Jingyuan Liu, Jian‐Ting Zhang · 2023 · Journal of Medicinal Chemistry
  21. All About the Core: A Therapeutic Strategy to Prevent Protein Accumulation with Proteasome Core Particle Stimulators
    Rachel A. Coleman, Darci Jones Trader · 2018 · ACS Pharmacology & Translational Science
  22. Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na+/K+-ATPase independent proteolysis
    Cheng‐Wei Yang, Hsing‐Yu Hsu, Hsin-Yu Chang, Yue‐Zhi Lee, Shiow‐Ju Lee · 2020 · Biochemical Pharmacology
  23. Exploiting E3 ligases for lung cancer therapy: The promise of DCAF-PROTACs
    Md Sadique Hussain, Lina Eltaib, Amita Joshi Rana, Mudasir Maqbool, Sumel Ashique, Mashael N. Alanazi, Yumna Khan, Mohit Agrawal · 2025 · Pathology - Research and Practice
  24. The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options
    Antonella Di Costanzo, Nunzio Del Gaudio, Lidio Conte, Lucia Altucci · 2020 · Cancers
  25. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
    Chao Wang, Yujing Zhang, Tingting Zhang, Lingyu Shi, Zhongmin Geng, Dongming Xing · 2022 · Journal of Enzyme Inhibition and Medicinal Chemistry
  26. Tumor Suppressor FBXW7 and Its Regulation of DNA Damage Response and Repair
    Huiyin Lan, Yi Sun · 2021 · Frontiers in Cell and Developmental Biology
  27. Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology
    Carlotta Cecchini, Sébastien Tardy, Valentina Ceserani, Jean-Philippe Paul. Theurillat, Léonardo Scapozza · 2020 · CHIMIA International Journal for Chemistry
  28. Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
    Yerim Jin, Yeongju Lee · 2024 · ChemMedChem
  29. A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase
    Jingjing Ruan, Dongdong Liang, Wenjing Yan, Yongwang Zhong, Daniel C. Talley, Ganesha Rai, Dingyin Tao, Christopher A. LeClair, Anton M. Simeonov, Ying‐Hua Zhang et al. · 2022 · Molecular Biology of the Cell
  30. Application of Hypoxia-Activated Prodrugs in Tumor Therapy: Design Strategies and Perspectives
    Shengyu Liu, Mijia Zhang, Xiangxi Sun, Peng George Wang, Guogang Zhang, Wenyan Li · 2025 · Journal of Medicinal Chemistry
  31. Development of Degraders of Cyclin-Dependent Kinases 4 and 6 Based on Rational Drug Design
    Huan He, Xingsen Zhang, Jie Wang, Qi Liu, Leihao Zhang, Chen Lu, Yuan Yuan, Zhenjiang Zhao, Honglin Li, Zhuo Chen · 2024 · Journal of Medicinal Chemistry
  32. Synthetic biology approaches for targeted protein degradation
    Rebecca P. Chen, Andrew S. Gaynor, Wilfred Chen · 2019 · Biotechnology Advances
  33. Recent advances of PROTACs technology in neurodegenerative diseases
    Chao Wang, Yujing Zhang, Shanbo Yang, Dongming Xing · 2023 · Arabian Journal of Chemistry
  34. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules
    Yuqing Liang, Kutty Selva Nandakumar, Kui Cheng · 2020 · Biochemical Pharmacology
  35. Lysosome and related protein degradation technologies
    Hongmei Zheng, Gangjian Li, Jingli Min, Xiangwei Xu, Wenhai Huang · 2023 · Drug Discovery Today
  36. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
    Stefanie Lindner, Christian Steinebach, Hannes Kehm, Martin Mangold, Michael Gütschow, Jan Krönke · 2019 · Journal of Visualized Experiments
  37. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
    Renshuai Zhang, Songbo Xie, Jie Ran, Te Li · 2024 · Journal of Cellular Physiology
  38. Cullin-RING Ligase 4 in Cancer: Structure, Functions, and Mechanisms
    Jingyi Cheng, Xin Bin, Zhangui Tang · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  39. Proteolysis-targeting Chimeras for Targeting Protein for Degradation
    Jianguo Qi, Gang Zhang · 2019 · Future Medicinal Chemistry
  40. Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
    Qiuzhi Zhou, Weixia Wang, Chunchu Deng · 2025 · Molecular Neurobiology
  41. DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
    Yanli Bi, Xiaoyu Chen, Bajin Wei, Linchen Wang, Longyuan Gong, Haomin Li, Xiufang Xiong, Yongchao Zhao · 2021 · Theranostics
  42. MST and TRIC Technology to Reliably Study PROTAC Binary and Ternary Binding in Drug Development
    Tanja Bartoschik, Andreas Zoephel, Klaus Rumpel, Alessio Ciulli, Charles T. R. Heffern · 2021 · Methods in molecular biology
  43. Contemporary trends in targeted protein degradation for neurodegenerative diseases
    Gulshan Kumar, Vaibhav Thakur, Satish Sardana, Vinod K. Tiwari, Dilip Sharma, Asim Kumar · 2025 · European Journal of Medicinal Chemistry
  44. AI-driven discovery of dual antiaging and anti-AD therapeutics via PROTAC target deconvolution of a super-enhancer–regulated axis
    Yuan Sun, Sai Liu, Long Chen, Zheng Zhou, Xin Yin, Yiting Shi, Haotian Li, Jinran Li, Yi Lü, Wei Jiang et al. · 2025 · Science Advances
  45. Targeted Protein Degradation: An Important Tool for Drug Discovery for “Undruggable” Tumor Transcription Factors
    Mengyuan Dai, Radhakrishnan Sridhar, Rui Li, Ruirong Tan, Kuo Yan, Gang Fan, Miao Liu · 2022 · Technology in Cancer Research & Treatment
  46. New Cysteine Covalent Modification Strategies Enable Advancement of Proteome‐wide Selectivity of Kinase Modulators
    Ivy A. Guan, Kayla Williams, Jolyn Pan, Xuyu Liu · 2021 · Asian Journal of Organic Chemistry
  47. PROTACting the kinome with covalent warheads
    Deep Rohan Chatterjee, Saumya Kapoor, Meenakshi Jain, Rudradip Das, Moumita Ghosh Chowdhury, Amit Shard · 2022 · Drug Discovery Today
  48. A comprehensive primer and review of PROTACs and their In Silico design
    Jacopo Zattoni, Paola Vottero, Gea Carena, Chiara Uliveto, Giulia Pozzati, Benedetta Morabito, Ebenezea Gitari, Jack A. Tuszyński, Maral Aminpour · 2025 · Computer Methods and Programs in Biomedicine
  49. PROTAC vaccine: A new way to live attenuated vaccines
    Zhen Li, Haiqing Bai, Xuetong Xi, Wen‐xia Tian, John Z.H. Zhang, Demin Zhou, Longlong Si · 2022 · Clinical and Translational Medicine
  50. First-in-class metallo-PROTAC as an effective degrader of select Pt-binding proteins
    Paul O'Dowd, Graeme P. Sullivan, Daniel Alencar Rodrigues, Tríona Ní Chonghaile, Darren M. Griffith · 2023 · Chemical Communications
  51. Role of TRIM24 in the regulation of proteasome-autophagy crosstalk in bortezomib-resistant mantle cell lymphoma
    Corentin Bouvier, María Gonzalez-Santamarta, Núria Profitós-Pelejà, Marc Armengol, Grégoire Quinet, Quentin Alasseur, Laurie Ceccato, Wendy Xolalpa, Raimundo Freire, Julie Guillermet‐Guibert et al. · 2025 · Cell Death Discovery
  52. Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues
    Can Zhao, Henian Wang, Wenhu Zhan, Xiaoqing Lv, Xiaodong Ma · 2023 · Journal of Medicinal Chemistry
  53. An updated review on the role of small molecules in mediating protein degradation
    Zumei Wu, Yulong Li, Jinyun Dong, Jiang‐Jiang Qin · 2025 · European Journal of Medicinal Chemistry
  54. Highly efficient and long-acting split-and-mix proteolysis targeting chimera based on self-assembled polylactic acid
    Meimiao Zhan, Hailing Chen, Meiling He, Chunli Song, Zi-Jun Jiao, Na Liu, Zhihong Liu, Zhanfeng Hou, Ying Chen, Zhibo Song et al. · 2025 · Nature Communications
  55. Towards Computational Models of Identifying Protein Ubiquitination Sites
    Lidong Wang, Ruijun Zhang · 2018 · Current Drug Targets
  56. Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer Immunotherapy
    Yujeong Moon, Hanhee Cho, Jinseong Kim, Sukyung Song, Jung Yeon Park, Jin Young Min, Eun Hee Han, Yongju Kim, Joon‐Kyung Seong, Man Kyu Shim et al. · 2024 · Angewandte Chemie
  57. The ubiquitin-proteasome system in Alzheimer’s disease: mechanism of action and current status of treatment
    Shanshan Jia, Quan Li, Xue Rui, Wen Qin, Wenhui Zhang, Jinjin Dou, Xiwu Zhang · 2025 · Frontiers in Aging Neuroscience
  58. The Activity of Novel BCR-ABL Small-Molecule Degraders Containing Pyrimidine Rings and Their Role in Overcoming Drug Resistance
    Xu Zhang, Linglan Tu, Haohuan Chai, Zilin Li, Yuhan Fu, Xiaoliang Zheng, Shenxin Zeng, Liyan Cheng · 2022 · Journal of Oncology
  59. PROTAC: A Novel Drug Delivery Technology for Targeting Proteins in Cancer Cells
    Rajni Bala, Rakesh Kumar Sindhu, Reecha Madaan, Shantanu K. Yadav · 2022 · Current Drug Discovery Technologies
  60. Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy
    Soumik De, Raghaba Sahu, Shubhendu Palei, Laxmi Narayan Nanda · 2024 · Bioorganic & Medicinal Chemistry
  61. How to rekindle drug discovery process through integrative therapeutic targeting?
    Ashok D. B. Vaidya, Anuradha Roy, Rathnam Chaguturu · 2018 · Expert Opinion on Drug Discovery
  62. Getting a Handle on Chemical Probes of Chomatin Readers
    Jarod M. Waybright, Lindsey Ingerman James · 2020 · Future Medicinal Chemistry
  63. Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design
    Tommaso Palomba, Giusy Tassone, Carmine Vacca, Matteo Bartalucci, Aurora Valeri, Cecilia Pozzi, Simon Cross, Lydia Siragusa, Jenny Desantis · 2022 · International Journal of Molecular Sciences
  64. N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances
    Suddhasatwa Banerjee, Sachin Sharma, Amandeep Thakur, Ritika Sachdeva, Ram Sharma, Kunal Nepali, Jing‐Ping Liou · 2023 · Current Drug Targets
  65. Design and Applications of Bifunctional Small Molecules in Biology
    Shelton R. Boyd, Lyra Chang, Wanderson Cabral de Rezende, Idris O. Raji, Prasanna Kandel, Secondra L. Holmes, Damian W. Young · 2020 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
  66. Lysine-Targeting Inhibitors of Amyloidogenic Protein Aggregation: A Promise for Neurodegenerative Proteinopathies
    Kazuma Murakami, Thi Hong Van Nguyen, Chioko Nagao, Kenji Mizuguchi, Gal Bitan · 2025 · JACS Au
  67. Emerging paradigms in bioorthogonal chemistry for future therapeutics
    Maide Önder, Fatma Zehra Yılmaz, Zeynep Demirsoy, Gülcihan Gülseren · 2025 · International Journal of Pharmaceutics
  68. Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins
    Morgane Daurat, Corentin Gauthier, Khaled El Cheikh, Lamiaa M. A. Ali, Elodie Morère, Nadir Bettache, Magali Gary‐Bobo, Alain Morère, Marcel Garcia, Marie Maynadier et al. · 2024 · Frontiers in Immunology
  69. Recent insight into the role of RING-finger E3 ligases in glioma
    Yang Cao, Hang Zhou, Xiaoyu Chen, Yin Li, Junwen Hu, Guoyang Zhou, Lin Wang · 2021 · Biochemical Society Transactions
  70. PROTACs: A Hope for Breast Cancer Patients?
    Rajwinder Kaur, Gaurav Chaudhary, Amritpal Kaur, Pargat Singh, Gagan Deep Longowal, Gayatri P. Sapkale, Sandeep Arora · 2021 · Anti-Cancer Agents in Medicinal Chemistry
  71. Research Progress of PROTACs in Breast Cancer: Subtype-Oriented Target Landscape, Clinical Stratification Evidence, and Engineering Strategies for Translation
    Senyang Guo, Jianhua Liu, Hongmei Zheng, Xinhong Wu · 2026 · Biomedicines
  72. Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
    A. Panwar, Mohd Imran Khan, Rajesh Kumar, Rakesh Kumar, Santosh Kumar Rai, Anil Kumar · 2024 · Advances in Alzheimer's Disease
  73. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
    Qing Yu, Xiufang Xiong, Yi Sun · 2020 · PubMed Central
  74. PROTAC-powered synergistic tumor therapy
    Xiaoyu Wang, Jingwen Zou, Yixuan Tao, Zhiwen Zhou, Changyu Bian, Zhiqiang Mao, Zhihong Liu · 2026 · TrAC Trends in Analytical Chemistry
  75. PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
    Mao Du, Tao Liu, Wenyu Wang, Shuai Fan, Mei Tian, Qing Du, Zhidong Wang, Xiaodong Li, Xiaoyu Liu, Qin Xia et al. · 2026 · European Journal of Medicinal Chemistry Reports
  76. Targeted Management: Unlocking the Crucial Role of PROTACs in Cancer Treatment
    Priyanka Gupta, Sumit Dutta, Prashant Kumar, Monika Kaushik, Sumel Ashique, Mithun Bhowmick · 2025 · Current Drug Discovery Technologies
  77. Tyrphostin AG1024 Suppresses Coronaviral Replication by Downregulating JAK1 via an IR/IGF-1R Independent Proteolysis Mediated by Ndfip1/2_NEDD4-like E3 Ligase Itch
    Cheng‐Wei Yang, Yue‐Zhi Lee, Hsing‐Yu Hsu, Guan-Hao Zhao, Shiow‐Ju Lee · 2022 · Pharmaceuticals
  78. Design, synthesis and biological evaluation of MNK-PROTACs
    Xue Sun, Qing‐Yun Wu, Hong Bu, Yifeng Pei, Dezhong Guan, Shi Guo, Jinpei Zhou, Huibin Zhang · 2024 · Molecular Diversity
  79. Evolution and impact of molecular glue research: a bibliometric analysis from 2000 to 2023
    Dian Li, Jingyi Cheng, Zhigen Yuan, Kexin Deng · 2024 · Frontiers in Oncology
  80. Discovery of the novel celastrol-based PROTACs for the treatment of non-small cell lung cancer
    Chunhui Ma, Fang Wang, Yiqing Wang, Fan Wu, Xuguang Zhang, Chuanhua Ding, Jifeng Zhao, Ying Ma, Wanzhong Li, Wen‐Shan Liu · 2025 · Molecular Diversity
  81. Transcription Factors, R-Loops and Deubiquitinating Enzymes: Emerging Targets in Myelodysplastic Syndromes and Acute Myeloid Leukemia
    Silvia M.L. Barabino, Elisabetta Citterio, Antonella Ellena Ronchi · 2021 · Cancers
  82. Harnessing nanobodies for target protein degradation through the Affinity-directed PROtein Missile (AdPROM) system
    Bill Carton, Sascha Röth, Thomas Macartney, Gopal P. Sapkota · 2022 · Methods in enzymology on CD-ROM/Methods in enzymology
  83. High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
    Kristin M. Riching, Sarah D. Mahan, Marjeta Urh, Danette L. Daniels · 2020 · Journal of Visualized Experiments
  84. Global Proteome Profiling to Assess Changes in Protein Abundance Using Isobaric Labeling and Liquid Chromatography-Tandem Mass Spectrometry
    Anthony P. Possemato, Kathryn Abell, Matthew P. Stokes · 2021 · Methods in molecular biology
  85. Ubiquitination in ischemic stroke: Molecular mechanisms and therapeutic implications
    Kun Zhang, Xuan Ruan, Ziyu Chen, Shuang Wang, Bin Hu, Zhonghui Wen, H Wang · 2026 · Brain Research Bulletin
  86. Antibody-mediated clearance of an ER-resident aggregate that causes glaucoma
    Minh Thu, Ahlam N. Qerqez, Kamisha R. Hill, Laura R. Azouz, Hannah A. Youngblood, Shannon E. Hill, Yemo Ku, Donna M. Pesciotta Peters, Jennifer A. Maynard, Raquel L. Lieberman · 2024 · PNAS Nexus
  87. Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradation
    Saooda Ibrahim, Muhammad Umer Khan, Saadia Noreen, Safia Firdous, Iqra Khurram, Raima Rehman, Muhammad Arshad Javed, Qurban Ali · 2025 · Cytotechnology
  88. A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition
    Rachel M. Sammons, Kevin N. Dalby · 2020 · Springer eBooks
  89. Post‐Covid Alzheimer and Its Remediation via PROTACs Therapy: A Comprehensive Review
    Teesta Bhowmick, Ritojo Basu, Arup Kumar Mitra, Sk Asfaque Ali, Ajoy Kumer, Bikram Dhara · 2025 · Health Science Reports
  90. Advances in AR-Targeting Chimeras: A Case Study of proteolysis-targeting Chimeras From Bench to Bedside
    Wu Du · 2022 · Future Medicinal Chemistry
  91. Targeted Protein Degradation: "The Gold Rush is On!"
    Daria Kotlarek, Agata Pawlik, Maria Sagan, Marta Sowała, Alina Zawiślak-Architek, Michał Walczak · 2020 · Technology Transfer and Entrepreneurship
  92. Plant E3 Ligases as Versatile Tools for Novel Drug Development and Plant Bioengineering
    Raed Al‐Saharin, Sutton Mooney, Hanjo A. Hellmann · 2020 · Royal Society of Chemistry eBooks
  93. Targeted Protein Degradation by Proteolysis Targeting Chimeras
    Wu Du · 2022
  94. Exploration of Potential Cyclin-dependent Kinases and their Inhibitors to Combat Abnormal Signalling and Cancer
    Pradeep Pilania, Sisir Nandi, Dinesh Kumar Meena, Brij Kishore Sharma · 2024 · Current Signal Transduction Therapy
  95. Synthesis of Two Versions of Carbon‐14‐Labeled ARV‐110: An Androgen Receptor PROTAC Degrader for Prostate Cancer
    Xuesong Dai, Bin Dong, Lei Xu, Zheng‐Min Yang · 2025 · Journal of Labelled Compounds and Radiopharmaceuticals
  96. Advances and challenges of targeted protein degradation in ophthalmology: Future directions and therapeutic potential
    Ke Feng, Mingyan Wei, Panqin Ma, Jiaoyue Hu, Caihong Huang, Yi Han, Zuguo Liu · 2025 · Materials & Design
  97. Design, synthesis, and pharmacological evaluation of novel isoindoline-based HPK1 degraders
    Zhisheng Zhang, Xuan Zhang, Tizhi Wu, Shengnan Shi, Jiahui Tu, Manqi Zhang, Yan Liang, Mengyang Ma, Sai Zhang, Guangyue Gong et al. · 2025 · European Journal of Medicinal Chemistry
  98. PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells
    Yeongji Kim, J E Kim, Junwon Choi, Jinhyeong Kim, Soyeon Park, Wonji Choi, Hyun‐Ju An, Jinman Kim, Minsup Kim, Sujin Choi et al. · 2026 · Cells
  99. Development of indole derived non-orthosteric inhibitors for Proto-oncogene serine/threonine-protein kinase PIM-1
    Benedikt W. Grau, Dhanir Tailor, Mallesh Pandrala, Katherine Schultz, En‐Chi Hsu, Arpit Dheeraj, Annah S. Rolig, Nicholas B. Struntz, Phuong Luong, Tanya Ivanova Stoyanova et al. · 2026 · European Journal of Medicinal Chemistry
  100. Engineered Lysosome-Targeted Protein Degradation via Hijacking Macropinocytosis
    Wen Xu, Henggong Pan, Yalan Han, Ling‐Yan Su, Hejiang Zhou · 2026 · ACS Nano